A20 deficiency in myeloid cells protects mice from diet-induced obesity and insulin resistance due to increased fatty acid metabolism

Graphical abstract

Highlights

- Myeloid A20 deficiency creates a pro-inflammatory environment in metabolic tissues
- Myeloid A20 deficiency protects mice from diet-induced obesity and insulin resistance
- Myeloid A20 deficiency promotes the expansion of inflammatory CD206+ ATMs
- A20-deficient macrophages metabolize more palmitate in vitro and in vivo

Authors

Leen Catrysse, Bastiaan Maes, Parul Mehrotra, ..., Kodi Ravichandran, Sophie Janssens, Geert van Loo

Correspondence

geert.vanloo@irc.vib-ugent.be

In brief

Catrysse et al. show that absence of A20 in myeloid cells leads to protection against diet-induced obesity and insulin resistance. They speculate that this is caused by increased oxygen consumption and increased fatty acid metabolism of A20-deficient macrophages. These findings reveal a role for A20 in regulating macrophage immunometabolism.
SUMMARY

Obesity-induced inflammation is a major driving force in the development of insulin resistance, type 2 diabetes (T2D), and related metabolic disorders. During obesity, macrophages accumulate in the visceral adipose tissue, creating a low-grade inflammatory environment. Nuclear factor-κB (NF-κB) signaling is a central coordinator of inflammatory responses and is tightly regulated by the anti-inflammatory protein A20. Here, we find that myeloid-specific A20-deficient mice are protected from diet-induced obesity and insulin resistance despite an inflammatory environment in their metabolic tissues. Macrophages lacking A20 show impaired mitochondrial respiratory function and metabolize more palmitate both in vitro and in vivo. We hypothesize that A20-deficient macrophages rely more on palmitate oxidation and metabolize the fat present in the diet, resulting in a lean phenotype and protection from metabolic disease. These findings reveal a role for A20 in regulating macrophage immunometabolism.

INTRODUCTION

The prevalence of obesity is steadily rising and has more than doubled since 1980. Obesity is closely associated with multiple metabolic disorders including insulin resistance and type 2 diabetes (T2D), non-alcoholic fatty liver disease, cardiovascular disease, and obesity-related cancers. Research over the past decade has established that obesity causes a condition of chronic low-grade inflammation, which is considered to lie at the origin of metabolic disease development (Gregor and Hotamisligil, 2011; Odegaard and Chawla, 2013). Macrophages play a central role in obesity-associated inflammation, and a lot of research has focused on the involvement of adipose tissue macrophages (ATMs) in this process (Catrysse and van Loo, 2018; Reilly and Saltiel, 2017). In steady state, the adipose tissue contains mainly tissue-resident CD206+ ATMs that have anti-inflammatory activity, promote tissue repair, and are important in maintaining adipose tissue homeostasis. In obese conditions, however, the adipose tissue becomes infiltrated with large numbers of CD11c+ macrophages that adopt a pro-inflammatory phenotype, leading to the secretion of pro-inflammatory cytokines including tumor necrosis factor (TNF) and interleukin (IL)-1β (Osborn and Olefsky, 2012). This phenotypic switch in macrophage activity is believed to be a main driving force in the development of the low-grade inflammatory state associated with obesity.

Of particular importance in establishing this inflammatory condition is the nuclear factor-κB (NF-κB) signaling pathway, which becomes activated in several metabolic tissues during obesity (Catrysse and van Loo, 2017; Köner and Brüning, 2011; Tanti et al., 2013). Previous studies have shown that inhibition of NF-κB signaling in myeloid cells protects against diet-induced systemic insulin resistance (Arkan et al., 2005). A crucial regulator of NF-κB activation is the anti-inflammatory protein A20 (also known as TNFAIP3 [tumor necrosis factor alpha induced protein 3]), which also has strong anti-apoptotic activities in many cell
types (Catrysse et al., 2014; Martens and van Loo, 2020). Interestingly, small nucleotide polymorphisms (SNPs) in or near the A20 locus have been identified in patients suffering from several autoimmune and inflammatory diseases, including atherosclerosis and T2D (Vereecke et al., 2011). In myeloid cells, A20 is essential in controlling inflammatory responses, hence, macrophages lacking A20 show an exacerbated NF-κB response leading to the increased production of pro-inflammatory cytokines (Matmati et al., 2011). As a result, myeloid-specific A20 knockout mice develop a spontaneous erosive polyarthritis (Matmati et al., 2011; Polykratis et al., 2019; Vande Walle et al., 2014; De Wilde et al., 2016).

Given the exacerbated inflammatory response of A20-deficient macrophages and the importance of pro-inflammatory CD11c+ macrophages in the pathophysiology of obesity, here we investigated the role of A20myel-KO mice in the context of obesity. Although A20myel-KO mice develop systemic inflammation with increased macrophage numbers when fed with a high-fat diet (HFD), they are completely protected from obesity and obesity-induced insulin resistance. CD206+ macrophages are shown to accumulate in the A20myel-KO adipose tissue after the HFD, although they have a gene signature indicative of classical pro-inflammatory macrophage activation. A20-deficient macrophages show impaired mitochondrial respiratory function and do not rely on intrinsic free fatty acid (FFA) oxidation, suggesting that they preferentially metabolize dietary fatty acids, resulting in the lean phenotype. Together, these findings reveal an unexpected role for A20 in regulating macrophage immunometabolism.

RESULTS

Myeloid A20 deficiency in mice creates a pro-inflammatory environment in metabolic tissues

A20myel-KO mice develop a systemic inflammatory pathology caused by hyperactive macrophages that uncontrollably produce inflammatory cytokines due to a prolonged NF-κB response (Matmati et al., 2011; Vande Walle et al., 2014). To investigate the consequence of these hyperactive macrophages in conditions of obesity, A20myel-KO mice and Cre-negative A20 “floxed” control littermates were subjected to either a HFD or a standard diet (SD), in contrast to wild-type control mice that gain weight and develop obesity upon HFD feeding (Figure 2A). In agreement, A20myel-KO mice show reduced adiposity, as the size of both eWAT and inguinal WAT (iWAT) (Figure 2B), as well as the fat mass (Figure 2C) are strongly reduced compared to control mice on the HFD. In addition, the adipocytes in A20myel-KO eWAT are smaller in size, but not reduced in number (Figure 1E; Figure S1A). Liver weight and liver triglycerides levels are not increased in A20myel-KO mice fed with the HFD, indicating that the lipids are not being stored in the liver (Figure S1B). Notably, the lean mass of A20myel-KO mice fed a HFD is even increased compared with control HFD mice, indicating that A20myel-KO mice are overall healthy and do not lose muscle mass (Figure 2C).

Interestingly, when fed with the SD, A20myel-KO mice show diminished body weight gain and epididymal fat pad size compared to control mice (Figures 2A and 2B), indicating that the lean phenotype of A20myel-KO mice is already present at steady state. The protection against HFD-induced obesity in A20myel-KO mice is further confirmed by a reduced hyperlipidemia, as measured by lower levels of cholesterol, triglycerides, and FFAs in the serum of A20myel-KO mice compared to control mice (Figure 2D). Transfer of A20-deficient bone marrow into wild-type donor mice is sufficient to protect against diet-induced obesity, while the transfer of wild-type bone marrow into lethally irradiated A20myel-KO mice is enough to revert the lean phenotype into an obesity phenotype (Figure 2E). This indicates that A20 deficiency in the myeloid cells is sufficient to induce protection against diet-induced obesity. Next, to investigate if induced deletion of A20 could revert obesity in already obese mice, we generated a tamoxifen-inducible A20 knockout mouse line by using the Cx3Cr1-ERT2-targeting strategy (A20Cx3Cr1-KO mice) and initiated A20 deletion after 10 weeks of HFD feeding. Indeed, tamoxifen-induced A20 deletion suppresses weight gain in these mice (Figure 2F).

ATMs play crucial roles in obesity-associated inflammation (Catrysse and van Loo, 2018; Reilly and Sattler, 2017). To address
the role of resident ATMs versus infiltrating macrophages in the protection of A20\textsuperscript{myel-KO} mice from diet-induced obesity, we generated A20-CCR2\textsuperscript{myel-DKO} mice lacking both A20 and the chemokine receptor CCR2 in the myeloid cell compartment. Since CCR2 signaling is essential for myeloid cell recruitment into the adipose tissue (Kanda et al., 2006; Weisberg et al., 2006), this approach allowed us to investigate the importance of the resident ATM population in the metabolic phenotype observed in A20\textsuperscript{myel-KO} mice. Since A20-CCR2\textsuperscript{myel-DKO} mice are also protected from HFD-induced obesity, this demonstrates that A20 deficiency in the resident ATMs is responsible for resistance to obesity (Figures S2A and S2B).

Myeloid A20 deficiency protects mice from diet-induced insulin resistance

Given the lean phenotype of A20\textsuperscript{myel-KO} mice and the well-known association between obesity and insulin resistance, we next analyzed glucose metabolism in A20\textsuperscript{myel-KO} mice and control wild-type littermates. Hyperglycemia is significantly reduced in A20\textsuperscript{myel-KO} mice compared to control mice after the HFD (Figure 3A). Also, neither hyperinsulinemia nor hyperleptinemia develops in A20\textsuperscript{myel-KO} mice in contrast to control mice fed with the HFD (Figure 3A). When subjected to an intraperitoneal glucose tolerance test (ipGTT), wild-type mice show severe glucose intolerance accompanied by an exacerbated insulin resistance (Figure 3A).
response after the HFD, but A20myel-KO mice display normal glucose and insulin responses, similar to mice fed with the SD (Figure 3B). Similarly, wild-type mice fed with the HFD develop systemic insulin resistance, while A20myel-KO mice are completely protected and respond normally to insulin after the HFD (Figure 3C).

We previously demonstrated that A20-deficient macrophages show an exacerbated inflammatory response and constitutively produce TNF and IL-6 (Matmati et al., 2011). As a consequence, A20myel-KO mice develop a severe erosive polyarthritis which is dependent on RIPK3-dependent macrophage necroptosis and NLRP3 inflammasome activation (Matmati et al., 2011; Polykratis et al., 2019; Vande Walle et al., 2014). To evaluate the metabolic response of A20 myel-KO mice to the HFD in conditions where the systemic inflammation is suppressed, A20myel-KO mice were crossed to Nlrp3 and Ripk3 knockout mice, and A20myel-KO/Nlrp3−/− and A20myel-KO/Ripk3−/− mice were subjected to HFD-induced obesity. However, these mice still show the protection from diet-induced obesity and insulin resistance similar to what is seen in A20myel-KO mice (Figures S2C and S2D). Liver and

eWAT from A20myel-KO/Ripk3−/− mice look identical to that of A20myel-KO mice after 10 weeks on the HFD. eWAT from A20myel-KO/Ripk3−/− mice shows the presence of infiltrating cells, but the adipocytes are much smaller than the adipocytes from wild-type and Ripk3−/− mice challenged with the HFD. Moreover, the typical CLSs, formed by infiltrating macrophages accumulating around dead adipocytes and evident in the eWAT from wild-type and Ripk3−/− mice after the HFD, are largely absent in the eWAT from both A20myel-KO and A20myel-KO/Ripk3−/− mice (Figure S2E). Also, liver tissue from A20myel-KO and A20myel-KO/Ripk3−/− mice looks similar after the HFD, demonstrating the presence of inflammatory foci mainly around the blood vessels but not the prominent inflammation, hepatocyte ballooning, and vacuoles of accumulated fat, reminiscent of steatohepatitis seen in liver tissue of wild-type and Ripk3−/− mice after the HFD (Figure S2F).

Together, these data demonstrate that the metabolic tissues of A20 myel-KO/Ripk3−/− mice are still inflamed, but do not show the typical hallmarks of obesity-associated inflammation, in agreement with the fact that these mice are protected from diet-induced obesity and insulin resistance.
Systemic treatment of A20\textsuperscript{myel-KO} mice with TNF- or IL6-neutralizing antibodies also does not revert the phenotype (Figures S2G and S2H). Finally, since A20\textsuperscript{myel-KO} mice were shown to have an enhanced activation of adaptive immune cells (Matsumi et al., 2011), we evaluated whether T and B lymphocytes are involved in the protection from diet-induced obesity in myeloid A20 knockout mice by crossing these mice with RAG2-deficient mice lacking functional T and B cells (Shinkai et al., 1992). Double homozygous A20\textsuperscript{myel-KO} RAG2\textsuperscript{--/--} mice still show protection from HFD-induced obesity (Figure S3), indicating that T and B cells are not responsible for the protection against obesity.

**Myeloid A20 knockout mice consume more oxygen but have normal thermogenesis**

To investigate the metabolic behavior of A20\textsuperscript{myel-KO} and control wild-type littermate mice in more detail, we measured metabolic rates of both genotypes by indirect calorimetry using metabolic chambers before and after 5 weeks of HFD. When control wild-type mice gain weight, their oxygen consumption increases (Figure 4A), confirming previous findings (Tschöp et al., 2011). Interestingly, A20\textsuperscript{myel-KO} mice have an even higher oxygen consumption, despite their leaner body composition, especially in the night phase when mice are more active (Figure 4A). The respiratory exchange ratio (RER), the ratio between the amount of carbon dioxide (VCO\textsubscript{2}) produced and oxygen (VO\textsubscript{2}) consumed during metabolism, gives an indication of the fuel source used to generate energy. Mice fed with the SD have an RER around 1, indicating their use of carbohydrates as a fuel source (Figure 4B). On the HFD, control mice predominantly use fat as a fuel source, lowering the RER to 0.7. However, A20\textsuperscript{myel-KO} mice show a higher RER in the night phase, indicating that they use a mix of fat and carbohydrates as a fuel source (Figure 4B). Also, A20\textsuperscript{myel-KO} mice consume even more food than control wild-type mice when fed the HFD, but no difference in locomotor activity can be observed between both groups of mice (Figure 4C). To check if the A20\textsuperscript{myel-KO} mice take up the lipids from the HFD, mice were starved overnight and refed for two hours, after which the small intestine was stained for presence of lipid droplets. Oil red O staining demonstrated that A20\textsuperscript{myel-KO} mice take up lipids from the diet to the same extent as wild-type littermates (Figure 4D). Together, these data indicate that the protective lean phenotype of A20\textsuperscript{myel-KO} mice is not due to reduced food intake, increased activity, or malabsorption of the diet. Instead, A20\textsuperscript{myel-KO} mice have a higher metabolic rate compared with control mice.

Protection against HFD-induced obesity is often explained by increased thermogenesis, which can be monitored by assessing the activity of uncoupling protein 1 (UCP1), the protein responsible for maintaining core body temperature and regulating body weight by increasing whole-body energy expenditure (Brestoff and Artis, 2015; Rosen and Spiegelman, 2014). However, no increased UCP1 staining nor increased expression of genes involved in thermogenesis could be observed in brown adipose tissue (BAT), the primary organ responsible for thermogenesis, of A20\textsuperscript{myel-KO} mice after the HFD (Figure 4E). Next to BAT, thermogenesis can also occur in the inguinal fat pad (iWAT) due to the transformation of white adipocytes into brown or “beige” adipocytes (Rosen and Spiegelman, 2014). However, no staining for UCP1 or increased gene expression could be detected in iWAT of A20\textsuperscript{myel-KO} mice after the HFD (Figure 4E). As thermogenesis is also dependent on the fat composition of the body, these experiments were repeated on lean, weight-matched, and individually housed wild-type and A20\textsuperscript{myel-KO} mice. However, no differences in expression of thermogenic markers, UCP1 staining of fat tissue, or body temperature could be observed between wild-type and A20\textsuperscript{myel-KO} littermate mice (Figure 4G), indicating that the absence of A20 in myeloid cells does not influence thermogenesis.
A. Day phase vs. Night phase

B. Respiratory exchange ratio

C. Food intake vs. Activity

D. Starved vs. 2h Refeed

E. UCP1 in iWAT and BAT of HFD WT vs. HFD A20myel-KO

F. Temperature

G. WT vs. A20myel-KO in UCP1 and BAT

(legend on next page)
Myeloid A20 deficiency promotes the expansion of highly inflammatory CD206+ ATMs

During obesity, the adipose tissue becomes infiltrated with pro-inflammatory CD11c+ macrophages that form characteristic CLSs around dying adipocytes (Osborn and Olefsky, 2012). In contrast, a lean state is associated with anti-inflammatory CD206+ macrophages that reside interstitially between adipocytes to maintain adipose tissue homeostasis (Osborn and Olefsky, 2012). Histology on fat tissue indeed shows the presence of CLS in eWAT of wild-type mice on the HFD, but this is strongly reduced in A20myel-KO mice (Figure 1E). However, flow cytometry of eWAT reveals that, despite their protected phenotype in obesity and insulin resistance, A20myel-KO mice display clear signs of eWAT inflammation, characterized by high numbers of macrophages and infiltrating monocytes, similar to the levels seen in the HFD wild-type mice (Figure 1D). The number of eosinophils was reduced in eWAT of A20myel-KO mice, while the number of granulocytes was higher, although to a much lower extent than the macrophage population (Figure S4). Further characterization of the eWAT-associated ATMs identified predominantly CD11clow CD206+ macrophages in A20myel-KO mice, while wild-type control mice fed with the HFD predominantly accumulate CD206low CD11c+ macrophages (Figures 5A and 5B). Interestingly, although ATMs from A20myel-KO mice show the same polarization as their lean counterparts, the absolute number of CD206+ macrophages is higher (Figure 5A). The CD11c+ macrophages mainly localize to CLSs around the dying adipocytes, which is evident in obese wild-type mice fed the HFD (Figure 5C). On the contrary, CD206+ macrophages localize interstitially between adipocytes, as demonstrated in eWAT of A20myel-KO mice and in control mice fed with the SD (Figure 5C).

To further investigate the function of the different macrophage populations in SD- and HFD-fed control and A20myel-KO mice, RNA sequencing (RNA-seq) was performed on fluorescence-activated cell sorting (FACS)-purified CD206+ and wild-type mice. Clustering analysis shows that ATMs isolated from A20myel-KO eWAT display a different gene expression pattern compared to wild-type ATMs, and this difference is already obvious in the lean condition (Figure 5D). Interestingly, A20myel-KO ATMs cluster together regardless of the diet (Figure 5D), and no genes are differentially regulated in each ATM subclass between the two diets in the absence of A20. This indicates that despite a similar lean body composition, there is an intrinsic difference between wild-type ATMs from mice fed with the SD and A20-deficient ATMs. Furthermore, CD11c+ and CD206+ macrophages are clearly separated in all conditions and are different between diets. Only the CD11c+ ATM population from wild-type HFD mice displays a more intermediate phenotype (Figure 5D), which is indicative of an ongoing polarization from a CD206highCD11clow state to a CD206lowCD11chigh state. IPA (Ingenuity Pathway Analysis) revealed that the gene pathways that show the most prominent differences between A20-deficient ATMs and wild-type ATMs are typical pro-inflammatory pathways, a signature which is independent of the CD11c+ or CD206+ classification and of the diet and is solely determined by the absence of A20 (Figure 5E; Figure S5A). Interestingly, A20-deficient ATMs have a higher expression of genes normally associated with obese ATMs (Nos2, Il6, Il12b, Ifng), despite being completely protected from HFD-induced obesity (Figure 5F; Figure S5B). Together, these data indicate that A20myel-KO mice have elevated numbers of mainly CD206+ ATMs. ATMs deficient of A20 display a general transcription profile similar to their lean wild-type counterparts based on the CD206+ and CD11c+ classification, but also have a pro-inflammatory signature, regulated by IFNγ and LPS, that is independent of the diet and is not present in wild-type ATMs.

Absence of A20 in macrophages leads to upregulation of Irg1 and increased palmitate consumption in vitro and in vivo

Analysis of the RNA-seq data demonstrated that immune responsive gene 1 (Irg1, also known as Acd1), is the second most highly upregulated gene between A20-deficient and wild-type ATMs (Figures S5C, SSD, and S6A). Irg1 is one of the highest upregulated genes in macrophages when stimulated in vitro with pro-inflammatory components such as LPS (lipopolysaccharide) and IFNγ (Degrandi et al., 2009; Strelko et al., 2011). Irg1 uses the tricarboxylic acid (TCA) cycle intermediate cis-aconitate to produce itaconic acid. Indeed, A20myel-KO mice show elevated levels of itaconic acid in their adipose tissue, and levels of itaconic acid are also increased in the serum of these mice (Figure S6B). Itaconic acid was recently identified as one of the key metabolites regulating the TCA cycle and the metabolic switch to aerobic glycolysis upon activation in macrophages (O’Neill and Artyomov, 2019). Therefore, we performed 13C tracing experiments to further investigate the metabolism of A20-deficient macrophages using 13C labeled glucose, glutamine, and palmitate (Figure 6A). The different tracers enter the TCA cycle and incorporate into the carbons of several
Figure 5. A20myel-KO mice display an increase of inflammatory CD206+ macrophages in their adipose tissue
(A and B) Quantification of the number of CD11c+ macrophages (CD206lowCD11chigh) and CD206+ macrophages (CD206highCD11clow) by flow cytometry on eWAT of WT and A20myel-KO mice after 12 weeks of the SD or HFD.
(C) Representative immunofluorescence microscopy images staining CD11c (green) and CD206 (red) on whole mount sections of eWAT of WT and A20myel-KO mice after 12 weeks of the SD or HFD. Scale bar, 100 μm.
metabolites. As the TCA cycle turns multiple rounds, the labeling will accumulate at the different carbon positions. Bone-marrow-derived macrophages (BMDMs) from wild-type and A20\(^{-/-}\) mice, unstimulated or stimulated with LPS and IFN\(\gamma\), were cultured for 48 hours in the presence of \(^{13}\)C labeled glucose, glutamine, or palmitate, and tracer incorporation was monitored in metabolites of the glycolysis and TCA using mass spectrometry. No differences in fractional contribution were found in the glycolysis pathway between wild-type and A20-deficient BMDMs (data not shown). Unstimulated wild-type and A20 knockout BMDMs, pulsed with \(^{13}\)C glucose, showed label incorporation in TCA cycle intermediates (albeit to different extents) (Figure 6B, first row). However, under stimulated conditions, TCA cycle intermediates of either wild-type or A20 knockout BMDMs did not get labeled. Rather, under stimulated conditions, glucose labeling was found to provide mainly an m2 isotope-pool of citrate (m2). This indicates that the flux of labeled carbons from glucose into the remaining TCA cycle intermediates was most likely interrupted, and that the majority of the cis-aconitate was being converted into itaconic acid, as can be observed by the high label incorporation in itaconic acid (Figure 6B, first row). The observed flux diversion, leading to depleted de novo label incorporation in the TCA cycle intermediates, prompted us to analyze if, under stimulated conditions, anaplerotic reactions compensate for the loss of flux into the TCA cycle. We labeled cells with \(^{13}\)C-glutamine and found an enhanced flux into the TCA cycle intermediates such as \(\alpha\)-ketoglutarate, fumaric acid, and malic acid under stimulated conditions for both wild-type and A20 knockout BMDMs (Figure 6B, second row).

Since in unstimulated A20 knockout BMDMs the fraction labeling of citrate was lower compared to wild-type BMDMs, and the labeling in itaconic acid was comparable between both, this indicates that A20-deficient cells most likely rely on another substrate source to produce the observed higher levels of itaconic acid (Figure 6B, first row). This difference cannot be explained by the contribution of glutamine, as a similar glutamine-derived labeling pattern is seen between wild-type and A20 knockout cells (Figure 6B, second row).

Interestingly, A20 knockout cells show a significant increase of palmitate contribution into citrate and itaconic acid, especially under stimulated conditions, indicating that they switch to palmitate oxidation to produce itaconic acid, in contrast to wild-type cells that use mainly glucose and glutamine for the synthesis of itaconic acid (Figure 6B, third row). Given this high palmitate labeling in itaconic acid, this suggests that A20 macrophages use palmitate to make itaconic acid, which could explain why the A20\(^{-/-}\) mice are protected from HFD-induced obesity.

To investigate if the higher levels of itaconate observed in A20\(^{-/-}\) mice provide protection from HFD-induced obesity, mice were crossed with either floxed Irg1 mice (Nair et al., 2018) to generate A20\(^{-/-}\)Irg1 double knockout (A20\(^{-/-}\)Irg\(^{1\text{myel-KO}}\)) mice or with full Irg1 knockout (A20\(^{-/-}\)Irg\(^{1\text{myel-KO}}\)) mice. However, these double knockout mice were still protected from HFD-induced obesity to the same extent as the A20\(^{-/-}\) mice, demonstrating that additional Irg1 deletion could not rescue the lean phenotype of A20\(^{-/-}\) mice (Figures S6C and S6D). Deletion of Irg1 and A20 was confirmed by qPCR on cultured peritoneal macrophages stimulated with IFN\(\gamma\) and LPS (Figure S6E). Circulating levels of itaconic acid are significantly lower in A20\(^{-/-}\)Irg\(^{1\text{myel-KO}}\) mice compared to the levels in A20\(^{-/-}\) mice, but still higher than the levels measured in the serum of control wild-type mice (Figure S6F), questioning the source of the remaining itaconic acid. As the activation status and corresponding metabolism of macrophages is highly dependent on the surrounding microenvironment and difficult to recapitulate ex vivo, we next performed an in vivo \(^{13}\)C palmitate labeling experiment. Wild-type and A20\(^{-/-}\) mice were injected with 3 \(\mu\)mol \(^{13}\)C palmitate dissolved in 1.2% lecithin/2.5% glycerol (\(^{13}\)C PA) or with 1.2% lecithin/2.5% glycerol alone, after which tracer metabolomics was performed on thioglycollate-elicited peritoneal fluid. The major drawback of in vivo metabolomics is the limited time frame between cell isolation and metabolite extraction. Therefore, we opted for thioglycollate-elicited peritoneal fluid since it contains a large macrophage population that can be quickly isolated (Figure S7). Labeling by \(^{13}\)C palmitate can be found in multiple metabolites, confirming efficient labeling (Figure 7A). Interestingly, A20\(^{-/-}\) mice show significantly more palmitate labeling in citric acid and especially in itaconic acid but also in metabolites downstream of itaconic acid such as fumaric acid and malic acid (Figure 7A). These data indicate that macrophages from A20\(^{-/-}\) mice have a preference to metabolize palmitate to fuel their metabolic flux also in vivo. To confirm, we assessed fatty acid uptake on macrophages isolated from different organs by using Bodipy-palmitate, a fluorescently tagged form of palmitic acid that allows us to monitor cellular fatty acid uptake (O’Sullivan et al., 2014). This demonstrates a stronger uptake of palmitate by macrophages in liver and spleen from A20\(^{-/-}\) mice compared to the uptake in wild-type mice (Figure 7B). In eWAT, a stronger uptake could be observed in A20\(^{-/-}\) macrophages but only in SD conditions. These data are in line with the RNA-seq analysis (Figures 5D–SF), revealing strong differences in gene expression in eWAT macrophages derived from wild-type and A20\(^{-/-}\) mice already in SD conditions, showing that the phenotype is readily apparent in baseline.

(D) RNA sequencing and cluster analysis on CD11c\(^{+}\) (CD206\(^{+}\)/CD11c\(^{+}\)) and CD206\(^{+}\) (CD206\(^{+}\)/CD11c\(^{-}\)) adipose tissue macrophages (ATMs) sorted from eWAT of WT and A20\(^{-/-}\) mice after 12 weeks of the SD or HFD (n = 4 per genotype).
(E) Table of top differentially regulated gene networks comparing gene expression from RNA sequencing data between A20\(^{-/-}\) and control WT CD11c\(^{+}\) and CD206\(^{+}\) ATMs after 12 weeks of the SD or HFD. Upregulated genes (red), downregulated genes (blue).
Data are represented as mean ± SEM; **p ≤ 0.01; ****p ≤ 0.0001.
To evaluate whether A20 deficiency affects mitochondrial function and biogenesis in macrophages, we performed an extracellular flux analysis in both BMDMs and in immortalized monocyte/macrophage HoxB8 progenitor cells derived from wild-type and A20
 "myel-KO" mice. Compared to wild-type macrophages, A20-deficient macrophages exhibit a strong and significant reduction in baseline oxygen consumption rate (OCR). This difference is even more pronounced after carbonyl cyanide p-(tri-fluromethoxy)phenyl-hydrazone (FCCP)-induced uncoupling during OXPHOS (oxidative phosphorylation), as shown by OCR and spare respiratory capacity (SRC), demonstrating that the A20 knockout cells have a reduced ability to increase their

Figure 6. A20-deficient macrophages have a preference to metabolize palmitate in vitro
(A) Scheme explaining 13C metabolic tracing. Labeled glucose, glutamine, or palmitate will enter the TCA cycle and label the first carbons of several metabolites. As the TCA cycle turns multiple cycles, the labeling will accumulate in the different carbon positions.
(B) WT or A20 knockout (KO) BMDMs were left untreated or stimulated with LPS/IFNγ (10ng/ml) and cultured for 48 hours with medium containing 13C labeled glucose, glutamine, or palmitate, after which the metabolites were analyzed for the tracer using mass spectrometry (n = 3). (m0), unlabeled carbon; (m1-6), the first through sixth carbon position in a metabolite.
energy production when using carbon sources readily available in the test medium (glucose, glutamine, and pyruvate) (Figures 7C–7E). We also showed that the cells do not rely on intrinsic FFA oxidation, since incubation with Etomoxir, an inhibitor of carnitine palmitoyl transferase 1 (CPT1) and a rate-limiting enzyme for beta-oxidation of fatty acids in mitochondria, does not affect OCR and SRC (Figure S8).

In conclusion, these data identify A20 as a crucial control on metabolic signaling and metabolic reprogramming in macrophages. Given the increased macrophage numbers in A20myel-KO
mice (Figures 1D and 1G), we hypothesize that these macrophages consume a large bulk of the fatty acids present in the HFD, resulting in the protection of A20\textsuperscript{myel-KO} mice against diet-induced obesity.

**DISCUSSION**

In this study, we describe an important role for the NF-κB regulatory protein A20 in myeloid cells during the development of obesity. We show that absence of A20 in myeloid cells leads to a complete protection against diet-induced obesity and insulin resistance.

During obesity, adipose tissue shows a dramatic shift from a type 2 to a more type 1 cytokine-associated immune environment, where the numbers of type 2 immune cells such as regulatory T cells (Tregs) and eosinophils gradually decrease, and the numbers of lymphocytes, granulocytes, and monocytes increase. This leads to a positive feedback, resulting in a chronic low-grade inflammatory state (Lumeng et al., 2007). Macrophages are major players in this process, and ATMs are known to switch from an anti-inflammatory CD206\textsuperscript{+} state to a pro-inflammatory CD11c\textsuperscript{+} state, augmenting the inflammatory response and affecting insulin sensitivity. In addition, newly recruited CD11c\textsuperscript{+} macrophages contribute to the inflammatory response (Osborn and Olefsky, 2012). Increased numbers of CD206\textsuperscript{+} macrophages can be detected in the adipose tissue of A20\textsuperscript{myel-KO} mice, in contrast to control mice which accumulate CD11c\textsuperscript{+} ATMs upon the HFD. However, the adipose tissue of A20\textsuperscript{myel-KO} mice shows an increased expression of pro-inflammatory cytokines, and RNA-seq of A20-deficient ATMs reveals an expression pattern related to IFN\gamma and LPS signaling, indicative of classical M1 polarization. This suggests that A20-deficient ATMs show aspects of pro-inflammatory signaling, which is different from the gene signature of CD11c\textsuperscript{+} macrophages seen in obese control mice. More recent studies based on unbiased “omics” approaches have also shown that the profile of ATMs that accumulate during obesity is different from the profile of classically activated inflammatory macrophages and show a metabolically activated profile reminiscent of arachidonic acid metabolism, glycerolipid metabolism, lipid binding, endocytosis, and phagocytosis (Hill et al., 2018; Kratz et al., 2014; Weinstock et al., 2019; Sharma et al., 2019; Silva et al., 2019; Xu et al., 2013). In addition, it is well established that the degree of inflammation correlates with the severity of insulin resistance (Hotamisligil, 2006; Lumeng and Saltiel, 2011; Reilly and Saltiel, 2017), and inflammation can induce insulin resistance independent of obesity (Tian et al., 2016). Our study indicates that our knowledge on the function of ATMs, the different ATMs subpopulations, and their respective contribution to obesity-associated inflammation is still limited. Studies using single-cell RNA-seq and other unbiased approaches could provide clarity on this matter and help redefine the hallmarks of obesity.

Clustering analysis of RNA-seq data shows that both the CD11c\textsuperscript{+} and CD206\textsuperscript{+} A20-deficient ATM populations on either diet are very different from their lean wild-type counterparts. The diet also does not affect gene expression in A20-deficient ATMs, as no genes are differentially regulated between standard and HFD in these ATM subpopulations. This shows that an intrinsic difference in A20-deficient ATMs causes the lean phenotype of A20\textsuperscript{myel-KO} mice.

Recent research has focused on the close interactions between inflammation and metabolism and has shown that especially immune cells adapt their metabolism according to their inflammatory state (Ghesquière et al., 2014). Recently, the metabolite itaconic acid was identified to be crucial in this aerobic switch, together with succinate (O’Neill and Artyomov, 2019). ATMs lacking A20 highly upregulate Igf1, the enzyme that generates itaconic acid. However, genetic deletion of Igf1 in A20\textsuperscript{myel-KO} mice could not reverse the lean phenotype. It is highly likely that there could be compensatory flux rerouting the excess of palmitate in the stable Igf1 knockout mice, leading to the maintenance of the lean phenotype. Stable knockouts of metabolic enzymes often lead to such outcomes, owing to the plasticity of metabolic networks.

We could further demonstrate that A20 plays an important role in metabolic signaling and metabolic reprogramming in macrophages by showing that A20-deficient macrophages rely more on palmitate oxidation to fuel the synthesis of itaconic acid and their metabolic flux. Since A20\textsuperscript{myel-KO} mice have low levels of FFAs and triglycerides in the serum, we hypothesize that these mice are protected from diet-induced obesity because their macrophages metabolize the fatty acids present in the diet. As a result, there is no nutritional excess, and no expansion of the adipose tissue will occur. Other studies have shown that the metabolism of macrophages can affect adiposity and responses to the HFD (Sharma et al., 2019; Wilson et al., 2018). How A20 controls fatty acid metabolism is still unclear and the subject of future research. Interestingly, an interactome analysis to find novel interaction partners of A20 identified the protein GPAT3 as an interaction partner for A20 (Eyckerman et al., 2016).
Glycerol-3-phosphate acyltransferases are the rate-limiting enzymes in fatty acid synthesis, and GPAT3 and GPAT4 knockout mice show increased energy expenditure and reduced adiposity, making this a potential candidate (Cao et al., 2014; Yu et al., 2018; Zhang et al., 2014).

In conclusion, deletion of A20 in myeloid cells leads to a complete protection from diet-induced obesity and insulin resistance, despite the presence of systemic inflammation. We speculate that the lean phenotype of A20myel−/− mice is caused by increased oxygen consumption and increased fatty acid metabolism of A20-deficient macrophages. However, further studies are needed to investigate the role of A20 in macrophage fatty acid metabolism in more detail.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **RESOURCE AVAILABILITY**
  - Lead contact
  - Materials availability
  - Data and code availability
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Animals
  - Cells
- **METHOD DETAILS**
  - Animals
  - DEXA scan
  - Analytical assays
  - Assessment of glycemic control
  - Indirect bocmacorilhemetry
  - Tissue histology and immunohistochemistry
  - Quantification of adipocytes
  - Flow cytometry
  - Immune cell labeling with BODIPY FL C16 (palmitate) and 2-NBDG
  - BMDM cell culture
  - Hoxb8 cells
  - In vivo 13C metabolomics tracing
  - In vivo 13C metabolomics tracing
  - Analysis of mitochondrial function
  - Bone marrow transfer
  - qPCR
  - RNA-sequencing
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2021.109748.

ACKNOWLEDGMENTS

We thank Manolis Pasparakis (Koeln University), Vishva Dixit (Genentech), and the Knockout Mouse Programme (KOMP) Repository for generous supply of mutant mice, and Louis Boon (Bioceros) for TNF- and IL6-neutralizing antibodies. We thank Laetitia Bellen and Dimitri Huyghebaert for animal care and are grateful to Marnik Vuylsteke for help with statistics. We acknowledge the VIB Bioimaging Core, the VIB Nucleosome Core, and the VIB Flowcore for technical assistance. L.C. was supported as a PhD fellow by the “Instituut voor Innovatie door Wetenschap en Technologie” (IWT) and by a research grant from “Kom op tegen Kanker.” E.H. holds an FWO postdoctoral fellowship and C.M. a postdoctoral fellowship from the German Research Foundation (DFG) (MA 7770/1-1). Research in the van Loo lab was also supported by research grants from the FWO, the “Belgian Foundation against Cancer,” the “Geneeskundige Stichting Koningin Elisabeth” (GSKE), the “Interuniversity Attraction Poles program” (IA7P), and the “Concerted Research Actions” (GOA) of the Ghent University.

AUTHOR CONTRIBUTIONS

L.C. and B.M. performed the bulk of the experiments, analyzed the data, and wrote the manuscript. P.M. performed the Seahorse experiments. E.H. performed the bone marrow transfer experiment. C.S., A.R., and A.B. performed the flow cytometry of the liver. K.S. helped with the experiments to investigate the fat uptake in the small intestine. A.M. and M.S. performed the in vitro 13C tracing experiments. B.G. performed the mass spectrometry analysis. L.M. and Y.S. analyzed the raw RNA-seq data. M.S. and H.V. provided help to L.C. during several experiments. C.M and K.R. provided tools and ideas, B.v.d.S. performed the indirect calorimetry experiments, R.K. and S.J. provided ideas and analyzed the data. G.v.L. provided ideas, analyzed the data, coordinated the project, and wrote the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: November 11, 2019
Revised: April 4, 2021
Accepted: September 2, 2021
Published: September 21, 2021

REFERENCES

Arkan, M.C., Hevener, A.L., Greten, F.R., Maeda, S., Li, Z.-W., Long, J.-M., Wynshaw-Boris, A., Poli, G., Olesfsky, J., and Karin, M. (2005). IKK-beta links inflammation to obesity-induced insulin resistance. Nat. Med. 11, 191–198.

Bonnardel, J., T’Jonck, W., Gaublomme, D., Browaeys, R., Scott, C.L., Martens, L., Vanneste, B., De Prijck, S., Nedospasov, S.A., Kremer, A., et al. (2019). Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. Immunity 51, 638–654.e9.

Brestoff, J.R., and Arts, D. (2015). Immune regulation of metabolic homeostasis in health and disease. Cell 161, 146–160.

Cani, P.D., Amar, J., Iglesias, M.A., Poggi, M., Knauf, C., Bastelica, D., Neyrinck, A.M., Fava, F., Tuohy, K.M., Chabo, C., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772.

Cao, J., Perez, S., Goodwin, B., Lin, Q., Peng, H., Qadri, A., Zhou, Y., Clark, R.W., Perreault, M., Tobin, J.F., and Gimeno, R.E. (2014). Mice deleted for A20 exhibit increased inflammation, cardiac insulin resistance, and polarization to M1 macrophages. PLoS ONE 9, e91049.

Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Förster, I. (1999). Conditional gene targeting in macrophages and granulocytes using LysMCre mice. Transgenic Res. 8, 265–277.
O’Neill, L.A.J., and Artyomov, M.N. (2019). Inflammasome: the poster child of metabolic reprogramming in macrophage function. Nat. Rev. Immunol. 19, 273–281.

O’Sullivan, D., van der Windt, G.J., Huang, S.C., Curtis, J.D., Chang, C.H., Buck, M.D., Qi, J., Smith, A.M., Lam, W.Y., DiPlato, L.M., et al. (2014). Memory CD8+ T cells use cell-intrinsic ilopiosis to support the metabolic programming necessary for development. Immunity 41, 75–88.

Odegaard, J.I., and Chawla, A. (2013). Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 339, 172–177.

Ogawa, Y., Imaio, K., Honda, Y., Kessoku, T., and Tomeno, W. (2018). Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. Sci. Rep. 8, 11365.

Osborn, O., and Ofesky, J.M. (2012). The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 18, 363–374.

Pajvani, U.B., Trujillo, M.E., Combs, T.P., Iyengar, P., Jelicke, L., Roth, K.A., Kitsis, R.N., and Scherer, P.E. (2005). Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11, 797–803.

Polykrist, A., Martens, A., Eren, R.O., Shirasaki, Y., Yamagishi, M., Yamaguchi, Y., Uemura, S., Miura, M., Holzmann, B., Kollis, G., et al. (2019). A20 prevents inflammasome-dependent arthritis by inhibiting macrophage necroptosis through its ZnF7 ubiquitin-binding domain. Nat. Cell Biol. 21, 731–742.

Reilly, S.M., and Saltiel, A.R. (2017). Adapting to obesity with adipose tissue inflammation. Nat. Rev. Endocrinol. 13, 633–643.

Rosen, E.D., and Spiegelman, B.M. (2014). What we talk about when we talk about fat. Cell 156, 20–44.

Sharma, M., Schlegel, M., Brown, E.J., Sansbury, B.E., Weinstock, A., Afonso, M.S., Corr, E.M., van Solingen, C., Shanley, L.C., Peled, D., et al. (2019). Neutrin-1 Alters Adipose Tissue Macrophage Fate and Function in Obesity. Immuno. Metabolism 1, 549–562.

Shinkai, Y., Rathbun, G., Lam, K.P., Oltz, E.M., Stewart, V., Mendelsohn, M., Charron, J., Datta, M., Young, F., Stait, A.M., et al. (1992). RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 88, 855–867.

Silva, H.M., Báfica, A., Rodrigues-Luiz, G.F., Chi, J., Santos, P.D.A., Reis, B.S., Hoytama van Konijnenburg, D.P., Crane, A., Anta, R.D.N., Martin, P., et al. (2019). Vasculature-associated fat macrophages readily adapt to inflammatory and metabolic challenges. J. Exp. Med. 216, 786–806.

Streich, K.L., Wu, L., Dufort, F.J., Seyfried, T.N., Chiles, T.C., Rabinowitz, J.D., and Roberts, M.F. (2011). Inflacitin is a mammalian metabolite induced during macrophage activation. J. Am. Chem. Soc. 133, 16386–16389.

Tanti, J.-F., Ceppo, F., Jager, J., and Berthou, F. (2013). Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front. Endocrin. (Lausanne) 3, 181.

Tian, X.Y., Ganeshan, K., Hong, C., Nguyen, K.D., Qi, Y., Kim, J., Tangirala, R.K., Tontonoz, P., and Chawla, A. (2016). Thermoneutral Housing Accelerates Metabolic Inflammation to Potentiate Atherosclerosis but Not Insulin Resistance. Cell Metab. 23, 165–178.

Tschoß, M.H., Speakman, J.R., Arch, J.R.S., Auwerx, J., Brüning, J.C., Chan, L., Eckel, R.H., Farese, R.V., Jr., Galan, J.E., Hambly, C., et al. (2011). A guide to analysis of mouse energy metabolism. Nat. Methods 9, 57–63.

Vande Walle, L., Van Opdenbosch, N., Jacques, P., Fossoul, A., Verheugen, E., Vogel, E., Beyaert, R., Elewaat, D., Kanneganti, T.D., van Loo, G., and Lamkanfi, M. (2014). Negative regulation of the NLRP3 inflammasome by A20 protects against arthritis. Nature 512, 69–73.

Vereecke, L., Sze, M., Mc Guire, C., Rogiers, B., Chu, Y., Schmidt-Supprian, M., Pasparakis, M., Beyaert, R., and van Loo, G. (2010). Enteroocyte-specific A20 deficiency sensitizes to tumor necrosis factor-induced toxicity and experimental colitis. J. Exp. Med. 207, 1513–1523.

Vereecke, L., Beyaert, R., and van Loo, G. (2011). Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem. Soc. Trans. 39, 1089–1091.
Wang, G.G., Calvo, K.R., Pasillas, M.P., Sykes, D.B., Häcker, H., and Kamps, M.P. (2006). Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat. Methods 3, 287–293.

Weinstock, A., Brown, E.J., Garabedian, M.L., Pena, S., Sharma, M., Lafaille, J., Moore, K.J., Fisher, E.A., Behavior, S., and Neoplasms, B. (2019). Single-Cell RNA Sequencing of Visceral Adipose Tissue Leukocytes Reveals that Caloric Restriction Following Obesity Promotes the Accumulation of a Distinct Macrophage Population with Features of Phagocytic Cells. Immunometabolism 1, e190008.

Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R.L., and Ferrante, A.W., Jr. (2006). CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 116, 115–124.

Wilson, A.M., Shao, Z., Grenier, V., Mawambo, G., Daudelin, J.F., Deja, A., Pilon, F., Popovic, N., Boulet, S., Parinot, C., et al. (2018). Neuropilin-1 expression in adipose tissue macrophages protects against obesity and metabolic syndrome. Sci. Immunol. 3, 1–15.

Wolf, M.J., Hoos, A., Bauer, J., Boettcher, S., Knust, M., Weber, A., Simonavicius, N., Schneider, C., Lang, M., Sturzl, M., et al. (2012). Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway. Cancer Cell 22, 91–105.

Xu, X., Grijalva, A., Skowronski, A., van Eijk, M., Serlie, M.J., and Ferrante, A.W., Jr. (2013). Obesity activates a program of lysosomal-dependent lipid metabolism in adipose tissue macrophages independently of classic activation. Cell Metab. 18, 816–830.

Yu, J., Loh, K., Song, Z.Y., Yang, H.Q., Zhang, Y., and Lin, S. (2018). Update on glycerol-3-phosphate acyltransferases: the roles in the development of insulin resistance. Nutr. Diabetes 8, 34.

Zhang, C., Cooper, D.E., Grevenkoed, T.J., Li, L.O., Klett, E.L., Eaton, J.M., Harris, T.E., and Coleman, R.A. (2014). Glycerol-3-phosphate acyltransferase-4-deficient mice are protected from diet-induced insulin resistance by the enhanced association of mTOR and rictor. Am. J. Physiol. Endocrinol. Metab. 307, E305–E315.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| UCP1                | Abcam  | Cat# ab10983; RRID:AB_2241462 |
| CD206-Biotin coupled| Bio-Rad| Cat# MCA223SBT; RRID:AB_1101315 |
| CD11c-eFluor660     | eBioscience | Cat# 50-0114-80; RRID:AB_11151322 |
| Ly6C-eFluor450      | eBioscience | Cat# 48-5932-82; RRID:AB_10805519 |
| CD45-BV510          | BioLegend | Cat# 103137; RRID:AB_2561392 |
| CD64-BV711          | Biolegend | Cat# 139311; RRID:AB_2563846 |
| F4/80-Biotin        | eBioscience | Cat# 13-4801-81; RRID:AB_466656 |
| Streptavidin- BV786 | BD     | Cat# 563858; RRID:AB_2869529 |
| CD206-APC           | Biolegend | Cat# 141707; RRID:AB_10896057 |
| Fixable live dead dye eFluor780 | eBioscience | Cat# 65-0865 |
| Siglec F-PE         | BD     | Cat# 552126; RRID:AB_394341 |
| CD11c-PE-Texas Red  | Invitrogen | Cat# MCD11C17; RRID:AB_10373971 |
| Gr1-PE Cy5          | eBioscience | Cat# 15-5931-81; RRID:AB_468812 |
| CD11b-PE Cy7        | BD     | Cat# 552850; RRID:AB_394491 |
| anti-rabbit-HRP     | Dako   | Cat# P0448; RRID:AB_2617138 |
| CD11c-PE-eFluor610  | eBioscience | Cat# 61-0114-82; RRID:AB_2574530 |
| Ly-6G-PE            | BD     | Cat# 551461; RRID:AB_394208 |
| Siglec F-PE         | BD     | Cat# 552126; RRID:AB_394341 |
| Ly-6C-eFluor450     | eBioscience | Cat# 48-5932-82; RRID:AB_10805519 |
| Streptavidin-BV605  | BD     | Cat# 563260; RRID:AB_2869476 |
| F4/80-eFluor450     | eBioscience | Cat# 48-4801-82; RRID:AB_1548747 |
| B220-APC            | eBioscience | Cat# 17-0452-81; RRID:AB_469394 |
| CD45-PE             | eBioscience | Cat# 12-0451-82; RRID:AB_465668 |
| CD3-PE Cy7          | Biolegend | Cat# 100219; RRID:AB_1732068 |
| Fixable Viability Dye eFluor506 | Life Technologies | Cat# 65-0866-18 |
| Ly-6G BD Optibuild BV650 | BD Biosciences | Cat# 740554; RRID:AB_2740255 |
| F4/80 BV786         | BioLegend | Cat# 123141; RRID:AB_2563667 |
| CD206 APC           | BioLegend | Cat# 141708; RRID:AB_10900231 |
| CD45 AlexaFluor 700 | Life Technologies | Cat# 56-0451-82; RRID:AB_891454 |
| MHCII APC-eFluor780 | eBioscience | Cat# 47-5321-82; RRID:AB_1548783 |
| Lyve-1 biotin       | eBioscience | Cat# 13-0443-82; RRID:AB_1724157 |
| streptavidin PE-CF594 | BD Biosciences | Cat# 562284; RRID:AB_11154598 |
| CD3e PE-Cy5         | eBioscience | Cat# 15-0042-83; RRID:AB_468699 |
| CD19 PE-Cy5         | eBioscience | Cat# 15-0193-83; RRID:AB_657673 |
| CD11c PE-Cy7        | eBioscience | Cat# 25-0114-82; RRID:AB_469590 |
| CD11b BUV395        | BD Biosciences | Cat# 563553; RRID:AB_2738276 |
| CD45-FITC           | eBioscience | Cat# 11-0451-82; RRID:AB_465050 |
| Ly6C-PE             | BD     | Cat# 560592; RRID:AB_1727556 |
| CD11b-BV421         | BD     | Cat# 562605; RRID:AB_11152949 |
| CD206-APC           | Biolegend | Cat# 141707; RRID:AB_10896057 |

### Chemicals, peptides, and recombinant proteins

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| TRIzol reagent      | Thermo Fisher Scientific | cat# 15596026 |
| collagenase type II | Sigma  | cat# 1764 |

(Continued on next page)
### REAGENT or RESOURCE SOURCE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| ACK lysis buffer    | Thermo Fisher Scientific | cat# A1049201 |
| DNase               | Roche  | cat# 04 536 282 001 |
| Brewer thioglycollate medium | Sigma | cat# B-2551 |
| L-glutamin          | Lonza  | cat# BE17-605F |
| RPMI 1640           | Caisson Labs | cat# RPP24-1LT |
| Sodium pyruvate     | Sigma-Aldrich | cat# S-8636 |
| Penicillin-Streptomycin | Gibco  | cat#15140-122 |
| fetal calf serum    | Bodinco | n/a |
| LPS (E. coli 0111:B4 strain) | InvivoGen | n/a |
| IFNγ                | Produced in house | n/a |
| Ficoll Paque Plus   | Sigma  | cat# GE17-1440-02 |
| BODIPY FL C16       | Thermo Fisher Scientific | cat# D-3821 |
| GM-CSF              | Produced in house | n/a |
| 2-NBDG              | Thermo Fisher Scientific | cat# N13195 |
| BD Horizon Brilliant Stain Buffer | BD Biosciences | cat# 566349 |
| recombinant mouse M-CSF | Produced in house | n/a |
| Estradiol           | Sigma  | cat# E8875 |
| Fibronectin         | Sigma  | n/a |
| Polybrene           | Sigma  | cat# TR-1003 |
| G418                | ThermoFisher Scientific | cat# 1013035 |
| Glycerol            | Biosolve | cat# 7122301 |
| Lecithin            | Wako chemicals | cat# 120-00832 |
| 13C labeled ethyl ester palmitic acid | Cambridge Isotope Laboratories | cat# CLM-3957-0 |
| Liberase TM         | Roche  | cat# 5401119001 |

### Critical commercial assays

| Critical commercial assays                  | SOURCE | IDENTIFIER |
|---------------------------------------------|--------|------------|
| Aurum Total RNA Isolation Mini Kit          | BioRad | cat# 7326820 |
| iScript cDNA synthesis kit                  | Bio-Rad Laboratories | cat# 1708890 |
| SensiFAST SYBR® No-ROX Kit                  | GeC Biotech | cat# CSA-01190 |
| RNeasy Plus Micro Kit                       | QIAGEN | cat# 74034 |
| XF96 cell culture plates                    | Agilent technologies | cat# 101085-004 |
| Seahorse XF Long Chain Fatty Acid Oxidation Stress Test Kit | Agilent technologies | cat# 103672-100 |
| Bioplex mouse TNF assay                     | Biorad | cat# 171G5023M |
| Bioplex mouse IL6 assay                     | Biorad | cat# 171G5007M |
| Bioplex mouse MCP1 assay                    | Biorad | cat# 171G5019M |
| Bioplex mouse RANTES assay                  | Biorad | cat# 171G5022M |
| Mouse IL-18 ELISA kit                       | MBL    | cat# 7625 |
| Free Fatty Acid Assay Kit                   | Abnova | cat# KA1667 |
| RayBio® Mouse Leptin ELISA kit              | RayBio Inc | cat# ELM-Leptin-1 |
| Triglyceride Colorimetric Assay Kit         | Cayman Chemical | cat# 10010303 |
| Ultra Sensitive Mouse Insulin ELISA kit     | Crystal Chem | cat# 90080 |
| Agilent RNA 600 Nano kit                    | Agilent Technologies | n/a |
| SMART-Seq V4 Ultra Low Input kit            | Takara | cat# 634888 |
| NEBNext Ultra DNA Library Prep kit          | New England Biolabs | cat# E7370S |

### Deposited data

| Deposited data                  | SOURCE | IDENTIFIER |
|----------------------------------|--------|------------|
| RNaseq data                      | this paper | GEO: GSE182155 |

### Experimental models: Cell lines

| Experimental models: Cell lines | SOURCE | IDENTIFIER |
|---------------------------------|--------|------------|
| mouse: primary macrophages (BMDM and peritoneal) | this paper | n/a |

(Continued on next page)
**Continued**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Hoxb8               | this paper | n/a |

**Experimental models: Organisms/strains**

| mouse: A20FL | Vereecke et al., 2010 | n/a |
| mouse: LysM Cre | Clausen et al., 1999 | n/a |
| mouse: Cx3CR1ERT2 Cre | Goldmann et al., 2013 | n/a |
| mouse: Irg1FL | Nair et al., 2018 | n/a |
| mouse: Nrnp3 Δ/Δ | Mariathasan et al., 2006 | n/a |
| mouse: Ripk3 Δ/Δ | Newton et al., 2004 | n/a |
| mouse: Rag2 Δ/Δ | Shinkai et al., 1992 | n/a |
| mouse: Ccr2FL | Wolf et al., 2012 | n/a |

**Oligonucleotides**

| qPCR primers | see Table S1 | n/a |

**Software and algorithms**

| ZEN (blue edition) | Zeiss | https://www.zeiss.com/microscopy/int/products/microscope-software/zen.html |
| FlowJo.10 | n/a | https://www.flowjo.com/ |
| GraphPad Prism 8 | n/a | https://www.graphpad.com/ |
| Fluostar Omega | BMG Labtech | https://www.bmglabtech.com/fluostar-omega/ |
| XCalibur version 4.2.28.14 | Thermo Scientific | n/a |
| MSigDB | n/a | https://www.gsea-msigdb.org/gsea/msigdb |

**Genstat v19**

| VSN International | n/a |

**Other**

| Axioscan Z1 | Zeiss | n/a |
| LSR Fortessa 4 laser cytometer | BD Biosciences | n/a |
| LightCycler 480 II | Roche | n/a |
| TissueLyser II | QIAGEN | n/a |
| Vanquish LC System | Thermo Scientific | n/a |
| Hilicon HILIC-Fusion(P) SS column SS | Achrom | n/a |
| Lumos Orbitrap mass spectrometer | Thermo Scientific | n/a |
| glucometer (Freestyle Lite) | Abbott | n/a |
| paramagnetic oxygen analyzer | Servomex Xentra 4100 | n/a |
| infrared gas analyzer | Servomex 1440 | n/a |
| mass-flow controller (Type 5850) | Brooks | n/a |
| passive infrared detectors | Optex Wonderex FX-35 | n/a |
| light microscope | Olympus BX51 | n/a |
| confocal fluorescent microscope | Zeiss | n/a |
| Cryostat | Microm HM560 | n/a |
| Nanodrop | Thermo Fisher Scientific | n/a |

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents may be directed to Geert van Loo (Lead contact; geert.vanloo@irc.vib-ugent.be).

**Materials availability**

Resources and reagents generated in this study are available from the Lead Contact but may require a Materials Transfer Agreement to be signed.
EXPERIMENTAL MODEL AND SUBJECT DETAILS

Animals
Mice with conditional loxP-flanked A20 (Vereecke et al., 2010) were crossed with LysM-Cre transgenic mice (Clausen et al., 1999) to generate a myeloid-specific A20 knockout mouse (A20\textsuperscript{myel-KO} mice), as previously described (Matmati et al., 2011). Alternatively, A20\textsuperscript{FL/FL} mice were crossed with Cx3Cr1ERT2Cre transgenic mice (Goldmann et al., 2013) and A20 deletion was induced by injecting mice subcutaneously at 4 places with 50 \( \mu \)l of Tamoxifen dissolved in corn oil (20 mg/ml) twice a week to induce continuous deletion of A20 in myeloid cells. A20\textsuperscript{myel-KO} mice were crossed with Irg1\textsuperscript{FL/FL} (Nair et al., 2018), CCR2\textsuperscript{FL/FL} (Wolf et al., 2012), NLRP3\textsuperscript{-/-} (Mariathasan et al., 2006), RIPK3\textsuperscript{-/-} (Newton et al., 2004) or Rag2\textsuperscript{-/-} (Shinkai et al., 1992) mice to generate A20-Irg1\textsuperscript{myel-DKO}, A20-CCR2\textsuperscript{myel-DKO}, A20\textsuperscript{myel-KO}/NLRP3\textsuperscript{-/-}, A20\textsuperscript{myel-KO}/RIPK3\textsuperscript{-/-} or A20\textsuperscript{myel-KO}/Rag2\textsuperscript{-/-} mice, respectively. A20\textsuperscript{myel-KO} mice were treated by intraperitoneal injection every 4 days with neutralizing anti-TNF antibodies (MP6-XT22 mAb, 20 mg/kg body weight), anti-IL-6 antibodies (20F3 mAb, 10 mg/kg body weight), and isotype control antibodies, as previously described (Matmati et al., 2011). All experiments were performed on mice backcrossed into the C57BL/6J genetic background for at least ten generations. Mice were housed in individually ventilated cages in a specific pathogen-free animal facility of the VIB Center for Inflammation Research. Male littermate mice were fed with either a standard diet (10% kcal fat, Research Diets Inc, D12450B) or a high fat diet (60% kcal fat, Research Diets Inc, D12492) from the age of 8 weeks on. All experiments on mice were performed according to institutional, national and European animal regulations.

Cells
Bone Marrow Derived Macrophages (BMDMs) were obtained from bone marrow cells flushed from mouse femurs and tibia, and cultured in RPMI 1640 supplemented with 40 ng/ml recombinant mouse M-CSF, 10% FCS, 1% penicillin/streptavidin and glutamine. Fresh M-CSF was added on day 3 and medium was refreshed on day 5. On day 7 cells were seeded and stimulated. Peritoneal macrophages were isolated by injecting mice intra-peritoneally with 3 ml of Brewer thiglycollate medium (Sigma, B-2551) 4 days before sacrifice. 5 ml of PBS with 5 mM EDTA was injected intra-peritoneally with a small needle, the abdomen was gently massaged and most of the liquid was again retracted using a larger needle. The cells were spun down at 300 g for 3 min, the supernatants was removed and the cells were counted and cultured overnight in RPMI, 10% FCS, 1% penicillin/streptavidin, glutamine and sodium pyruvate. Immortalized macrophage Hoxb8 cells were generated as described previously (Wang et al., 2006). In short, bone marrow cells were collected from femur and tibia of 8 week old mice by flushing with RPMI (ThermoFisher Scientific). Progenitor cells were purified by centrifugation over 3 ml Ficoll Paque Plus (Sigma), and resuspended in progenitor outgrowth medium (POM) consisting of RPMI (ThermoFisher Scientific) supplemented with 10% FCS (Bodinco), 1% penicillin/streptomycin (ThermoFisher Scientific), 20 ng/ml GM-CSF (produced by the VIB Protein Core Facility) and 1 \( \mu \)M \( \beta \)-estradiol (Sigma). 250.000 cells per well were plated in 1 ml of POM in a fibronectin (Sigma) coated 12-well plate. Cells were infected by spinoculation (1000 g for 1 h) with Hoxb8-ER retroviral particles and in presence of 0.8 ug/ml polybrene (Sigma). 3 ml of POM was added after spinfection. After 24 h, cells were collected, pelleted by centrifugation and seeded in POM containing 1 \( \mu \)g/ml G418 (ThermoFisher Scientific) in 12-well suspension plates. Cells were split every 3-4 days until cell populations were stably expanding. For differentiation to macrophages, cells were washed twice with PBS to remove residual \( \beta \)-estradiol and plated at 10\textsuperscript{5} cells per 10 cm bacterial plate in 10 ml complete medium containing 50 ng/ml M-CSF. On day 3, 10 ml fresh medium was added, on day 5 medium was completely refreshed, and on day 6 cells were seeded in TC-coated plates.

METHOD DETAILS

Animals
Mice with conditional loxP-flanked A20 (Vereecke et al., 2010) were crossed with LysM-Cre transgenic mice (Clausen et al., 1999) to generate a myeloid-specific A20 knockout mouse (A20\textsuperscript{myel-KO} mice), as previously described (Matmati et al., 2011). Alternatively, A20\textsuperscript{FL/FL} mice were crossed with Cx3Cr1ERT2Cre transgenic mice (Goldmann et al., 2013) and A20 deletion was induced by injecting mice subcutaneously at 4 places with 50 \( \mu \)l of Tamoxifen dissolved in corn oil (20 mg/ml) twice a week to induce continuous deletion of A20 in myeloid cells. A20\textsuperscript{myel-KO} mice were crossed with Irg1\textsuperscript{FL/FL} (Nair et al., 2018), CCR2\textsuperscript{FL/FL} (Wolf et al., 2012), NLRP3\textsuperscript{-/-} (Mariathasan et al., 2006), RIPK3\textsuperscript{-/-} (Newton et al., 2004) or Rag2\textsuperscript{-/-} (Shinkai et al., 1992) mice to generate A20-Irg1\textsuperscript{myel-DKO}, A20-CCR2\textsuperscript{myel-DKO}, A20\textsuperscript{myel-KO}/NLRP3\textsuperscript{-/-}, A20\textsuperscript{myel-KO}/RIPK3\textsuperscript{-/-} or A20\textsuperscript{myel-KO}/Rag2\textsuperscript{-/-} mice, respectively. A20\textsuperscript{myel-KO} mice were treated by intraperitoneal injection every 4 days with neutralizing anti-TNF antibodies (MP6-XT22 mAb, 20 mg/kg body weight), anti-IL-6 antibodies (20F3 mAb, 10 mg/kg body weight), and isotype control antibodies, as previously described (Matmati et al., 2011). All experiments were performed on mice backcrossed into the C57BL/6J genetic background for at least ten generations. Mice were housed in individually ventilated cages in a specific pathogen-free animal facility of the VIB Center for Inflammation Research. Male littermate mice were fed with either a standard diet (10% kcal fat, Research Diets Inc, D12450B) or a high fat diet (60% kcal fat, Research Diets Inc, D12492) from the age of 8 weeks on. All experiments on mice were performed according to institutional, national and European animal regulations.

Data and code availability

- All data and code supporting the findings of this study are available within the paper or are available from the lead contact upon request.
- RNA-seq data have been deposited at Gene Expression Omnibus (GEO) and are publicly available with accession number GEO: GSE182155.
- Any additional information required to reanalyze the data reported in this work paper is available from the Lead Contact upon request.
A20-CCR2myel-DKO, A20myel-KOIRP3−/−, A20myel-KOIRPK3−/− or A20myel-KORag2−/− mice, respectively. A20myel-KO mice were treated by intraperitoneal injection every 4 days with neutralizing anti-TNF antibodies (MP6-XT22 mAb, 20 mg/kg body weight), anti-IL-6 antibodies (20F3 mAb, 10 mg/kg body weight), and isotype control antibodies, as previously described (Matmati et al., 2011). All experiments were performed on mice backcrossed into the C57BL/6J genetic background for at least ten generations. Mice were housed in individually ventilated cages in a specific pathogen-free animal facility of the VIB Center for Inflammation Research. Mice were fed with either a standard diet (10% kcal fat, Research Diets Inc, D12450B) or a high fat diet (60% kcal fat, Research Diets Inc, D12492) from the age of 8 weeks on. All experiments on mice were performed according to institutional, national and European animal regulations.

**DEXA scan**

DEXA scanning was used to measure percentage of total body fat, lean mass and fat mass. These measurements were performed as described (Pajvani et al., 2005).

**Analytical assays**

Cytokines (TNF, MCP-1, IL-6, RANTES) were measured in the serum of the mice using the Bioplex® Multiplex Immunoassay System (Biorad). IL-18 levels were determined using the Mouse IL-18 ELISA kit (MBL, 7625). Free fatty acid levels were determined using the Free Fatty Acid Assay Kit (Abnova, KA1667) and leptin levels were determined using the RayBio® Mouse Leptin ELISA kit (RayBio Inc). All assays were performed according to the manufacturer’s instructions. Triglyceride and cholesterol levels were determined from serum in the Laboratory of Clinical Biology of the University Hospital Ghent, according to standard procedures. Triglyceride levels in liver was determined using the Triglyceride Colorimetric Assay Kit (Cayman Chemical, 10010303). Itaconic acid levels were determined using the Lumos Orbitrap mass spectrometer (Thermo Scientific) and LC-Q-Exactive.

**Assessment of glycaemic control**

For the intraperitoneal glucose tolerance test (ipGTT), mice were injected with 2 g/kg glucose after an overnight fast. Tail blood samples were collected at indicated time points after injection, and glucose levels were determined using a glucometer (Freestyle Lite, Abbott). Serum insulin levels were determined by the Ultra Sensitive Mouse Insulin ELISA kit (Crystal Chem, 90080). For the insulin tolerance test (ITT), mice were injected with 0.75 U of insulin/g body weight after a 4 hour starvation period, and glucose levels were determined from tail blood by using a glucometer.

**Indirect bombcalorimetry**

Animals were housed individually in metabolic cages for 4 to 7 days. Oxygen and carbon dioxide concentration of dried inlet and outlet air from each chamber were measured with a paramagnetic oxygen analyzer (Servomex Xentra 4100) and carbon dioxide by an infrared gas analyzer (Servomex 1440). Flow rate of inlet air (60 l/hour) was measured with a mass-flow controller (Type 5850 Brooks). Ambient temperature in the room and chambers, as well as behavioral activity were measured simultaneously with passive infrared detectors (Optex Wonderex FX-35). Measurements were collected every 10 minutes (allowing optimal air mixing) for each animal and automatically stored on a computer. To reduce novel cage stress, the respirometric chambers (45x25x30 cm) were adapted to accommodate the home cage of the animal. Animals were measured at an ambient temperature of 22°C and food and water were provided *ad libitum*. Food intake was measured by manually weighing the food provided to the individual mice.

**Tissue histology and immunohistochemistry**

Histology was performed on paraffin-embedded (5 μm) tissue sections. Briefly, tissues were dissected and fixed in 4% paraformaldehyde and embedded in paraffin. Hematoxylin and eosin staining was performed according to a standard protocol using the Varistain (Thermo Fisher Scientific). For UCP1 staining, a UCP1-specific antibody (Abcam, ab10983) was used at a dilution of 1:500 followed by staining with Envision anti-Rabbit HRP (Dako). Images were taken with an Olympus BX51 light microscope. For immunofluorescence microscopy, whole mount adipose tissue was used, and adipose tissue (5 mm3) was left to dry on a slide coated with CellTAK (Coming) and stained with anti-CD206-Biotin coupled (AbD Serotec, MCA2235BT) and anti-CD11c-eFluor660 (eBioscience, 50-0114) for 24 hours, after which the slides were mounted and imaged using a confocal fluorescent microscope (Zeiss). For the Oil Red O staining, the small intestine was isolated, fixed in 4% paraformaldehyde for one hour, left overnight in 30% sucrose in PBS, prepared for freeze sections in Mec-60 and cut at 10 micron on a cryostat (Microm HM560). The slides were washed with PBS, washed with absolute propylene glycol for 5 minutes, stained with pre-warmed 0.5% Oil Red O dissolved in propylene glycol at 60 degrees for 10 minutes, destained with 85% propylene glycol for 5 minutes, washed under running tap water, counterstained with hematoxylin, mounted and imaged with an Olympus BX51 light microscope.

**Quantification of adipocytes**

5 μm sections from a complete eWAT fat pad were stained with hematoxylin and eosin and imaged using the slide scanner AxioScan Z1 (Zeiss), allowing visualization of the entire fat pad. Number and size of adipocytes were quantified using Fiji software.
Flow cytometry
Epididymal fat pads were isolated from mice, weighed and put in cold PBS + 0.5% BSA. Briefly, the fat pad was cut into pieces and digested in DMEM + 0.5% BSA + 10 mM CaCl₂ supplemented with 2 mg/ml collagenase type II (Sigma, 1764) at 37°C until single cell suspension. After collagenase neutralization with cold PBS + 0.5% BSA, the suspension was filtered through a 100 μm filter, washed and treated with ACK lysis buffer (Thermo Fisher Scientific). Cells were resuspended in FACS buffer (PBS, 0.5% BSA, 2 mM EDTA), counted and diluted to a concentration of 10 million cells/ml. Cells were stained with the following antibodies: Ly6C-eFluor450 (eBioscience, 48-5932-82), CD45-BV510 (BioLegend, 103137), CD64-BV711 (Biolegend, 139311), F4/80-Biotin (eBioscience, 13-4801-82), Streptavidin- BV786 (BD, 563858), CD206-APC (Biolegend, 141707), Fixable live dead dye eFluor780 (eBioscience, 65-0865), Siglec F-PE (BD, 552126), CD11c-PE-Texas Red (Invitrogen, MCD11C17), Gr1-PE Cy5 (eBioscience, 15-5931), CD11b-PE Cy7 (BD, 552850). After filtration diluted through a 30 μm filter, cells were analyzed on the LSR Fortessa 4 laser cytometer (BD). CountBright beads (Molecular probes) were used for the quantification of cells and normalized to the weight of the analyzed eWAT. For the isolation of liver leukocytes, livers were isolated from PBS-perfused mice, chopped finely and subjected to GentleMACS dissociation and incubated for 20 min with 1 mg/ml Collagenase A (Sigma) and 10U/ml DNase (Roche) in a shaking water bath at 37°C. Following a second round of GentleMACS dissociation, single cell suspensions were filtered over a 100 μm filter. Cells were resuspended in FACS buffer and stained with the following antibodies: Fixable live dead dye eFluor780 (eBioscience, 65-0865), CD11c-PE-eFluor610 (eBioscience, 61-0114-82), Ly-6G-PE (BD, 552126), Ly-6C-eFluor450 (eBioscience, 48-5932-82), CD11b-PE-Cy7 (BD, 552850), F4/80-Biotin (eBioscience, 13-4801-85), Streptavidin-BV605 (BD, Horizon 563260) and CD64-BV711 (Biolegend, 139311). For the peritoneal fluid, 200 μl of fluid was centrifuged for 3 min at 300 x g and stained with the following antibodies: F4/80-eFluor450 (eBioscience, 48-4801-82), CD64-BV711 (Biolegend, 139311), B220-APC (eBioscience, 17-0452-81), Fixable live dead dye eFluor780 (eBioscience, 65-0865), CD45-PE (eBioscience, 12-0451), CD3-PE Cy7 (Biolegend, 100219). After filtration through a 30 μm filter, cells were analyzed on the LSR Fortessa 4 laser cytometer (BD).

Immune cell labeling with BODIPY FL C16 (palmitate) and 2-NBDG
Mice were kept on standard or high fat diet as described before. Epididymal fat pads were isolated from mice, weighed and put in cold PBS + 0.5% BSA and processed as described earlier. Spleen cells were isolated and kept on ice cold RPMI 1640 (Thermo Fisher Scientific) until processing. Next, spleens were smashed over a 70 μm mesh filter, washed and after centrifugation treated with ACK lysis buffer (Thermo Fisher Scientific) to remove red blood cells. Liver cells were isolated by liver perfusion and digestion as previously described (Bonnardel et al., 2019). Briefly, after retrograde cannulation, livers were perfused for 1-2 mins with an EGTA-containing solution, followed by a 5 min (6 ml/min) perfusion with 0.2 mg/ml Collagenase A. Livers were then removed, minced and incubated for 20 min with 0.4 mg/ml Collagenase A and 10 U/ml DNase at 37°C. All subsequent procedures were performed at 4°C. Samples were filtered over a 100 μm mesh filter and red blood cells were lysed. Samples were again filtered over a 40 μm mesh filter. After two centrifugation steps of 1 min at 50 g to remove hepatocytes, remaining liver cells (leukocytes, LSECs and HSCs) were centrifuged at 400 g for 5 min. Next, eWAT, spleen and liver immune cells were resuspended in PBS, counted and 0.5-1 x 10⁶ cells were seeded in a 96-well plate. Cells were incubated with 2-NBDG (100 μM; Thermo Fisher Scientific, N13195) diluted in RPMI 1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin and 55 μM β-mercaptoethanol for 10 min at 37°C. For assaying BODIPY FL C16 (Thermo Fisher Scientific, D-3821) uptake, cells were incubated with the reagent (1 μM) diluted in RPMI 1640 (Thermo Fisher Scientific) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin and 55 μM β-mercaptoethanol for 30 min at 37°C. Uptake was stopped by adding ice cold PBS, after which cells were washed before proceeding to staining with fluorescent labeled antibodies. To allow broad immunophenotyping of substrate labeled immune cells, cells were stained with following antibodies/reagents diluted in BD Horizon Brilliant Stain Buffer (BD Biosciences, 566349): Ly-6C-eFluor450 (eBioscience, 48-4801-82), Fixable Viability Dye eFluor506 (Life Technologies, 65-0866-18), Ly-6G BD OptiBuild BV650 (BD Biosciences, 740554), CD64 BV711 (BioLegend, 139311), F4/80 BV786 (BioLegend, 123141), CD206 APC (BioLegend, 141708), CD45 AlexaFluor 700 (Life Technologies, 56-0451-82), MHCII APC-eFluor780 (eBioscience, 47-5321-82), Siglec F-PE (BD Biosciences, 552126), Lyve-1 biotin (eBioscience, 13-0443-82), streptavidin PE-CF594 (eBioscience, 562284), CD3e PE-Cy5 (eBioscience, 15-0042-83), CD19 PE-Cy5 (eBioscience, 15-0193-83), CD11c PE-Cy7 (eBioscience, 25-0114-82), CD11b BUVE35 (BD Biosciences, 563553). After filtration through a 40 μm filter, cells were analyzed on the LSR Fortessa 5 laser cytometer (BD).

BMDM cell culture
Bone Marrow Derived Macrophages (BMDMs) were obtained from bone marrow cells flushed from mouse femurs and tibia with ice-cold sterile RPMI medium, and cultured in RPMI 1640 supplemented with 40 ng/ml recombinant mouse M-CSF, 10% FCS, 1% penicillin/streptavidin and glutamine. Fresh M-CSF was added on day 3 and medium was refreshed on day 5. On day 7 cells were seeded and stimulated. Peritoneal macrophages were isolated by injecting mice intra-peritoneally with 3 mL of Brewer thioglycollate medium (Sigma, B-2551) 4 days before sacrifice. 5 mL of PBS with 5 mM EDTA was injected intra-peritoneally with a small needle, the abdomen was gently massaged and most of the liquid was again retracted using a larger needle. The cells were spun down at 300 g for 3 min, the supernatants was removed and the cells were counted and cultured overnight in RPMI, 10% FCS, 1% penicillin/streptavidin, glutamine and sodium pyruvate. After washing, the cells were stimulated for 16 h with 100 ng/ml LPS (E. coli 0111:B4 strain, InvivoGen) and 100 ng/ml IFNy (produced by the VIB Protein Core Facility) and RNA was isolated.
Hoxb8 cells

Immortalized macrophage progenitors were generated as described previously (Wang et al., 2006). Bone marrow cells were collected from femur and tibia of 8 week old mice by flushing with RPMI (ThermoFisher Scientific). Progenitor cells were purified by centrifugation over 3 mL Ficoll Paque Plus (Sigma). Cells were resuspended in progenitor outgrowth medium (POM) consisting of RPMI (ThermoFisher Scientific) supplemented with 10% FCS (Bodinco), 1% penicillin/streptomycin (ThermoFisher Scientific), 20 ng/ml GM-CSF (produced by the VIB Protein Core Facility) and 1 μM β-estradiol (Sigma). 250,000 cells per well were plated in 1 mL of POM in a fibronectin (Sigma) coated 12-well plate. Cells were infected by spinoculation (1000 g for 1 h) with Hoxb8-ER retroviral particles and in presence of 0.8 μg/ml polybrene (Sigma). 3 mL of POM was added after spinfection. After 24 h, cells were collected, pelleted by centrifugation and seeded in POM containing 1 μg/ml G418 (ThermoFisher Scientific) in 12-well suspension plates. Cells were split every 3-4 days until cell populations were stably expanding. For differentiation to macrophages, cells were washed twice with PBS to remove residual β-estradiol and plated at 10^6 cells per 10 cm bacterial plate in 10 mL complete medium containing 50 ng/ml M-CSF. On day 3, 10 mL fresh medium was added, on day 5 medium was completely refreshed, and on day 6 cells were seeded in TC-coated plates.

In vitro 13C metabolomics tracing

On day 7 BMDMs were seeded and stimulated with 10 ng/ml ultrapure LPS (E. coli 0111:B4 strain, InvivoGen) and 10 ng/ml IFNy (Protein Core Facility) dissolved in RPMI 1640 (Caisson Labs, #RPP24-1LT) supplemented with 1% penicillin/streptomavidin. The three tracing metabolites glucose (550 mM), glutamine (200 mM) and palmitic acid (150 mM) conjugated to BSA were added in equal amounts in either 13C or 12C form, depending on the condition. After two days, the cells were washed in cold 13C NaCl solution and the metabolites were extracted using an 80% methanol (in water) extraction buffer containing 2 μM of deuterated (d27) myristic acid as internal standard, spun down at 20 000 g for 10 min at 4 degrees, after which the supernatant was analyzed on a Vanquish LC System (Thermo Scientific) in-line connected to a Lumos Orbitrap mass spectrometer (Thermo Scientific). 5 μl of the sample was injected and concentrated on a Hilicon iHILIC-Fusion(P) SS precolumn after which it was loaded onto a Hilicon iHILIC-Fusion(P) SS column SS (Achrom). A linear gradient was carried out starting with 90% solvent A (LC-MS grade acetonitrile) and 10% solvent B (10 mM ammoniumacetate pH 9.3). From 2 to 20 minutes the gradient changed to 80% B and was kept at 80% until 23 min. Next a decrease to 40% B was carried out to 25 min, further decreasing to 10% B at 27 min. Finally 10% B was maintained until 35 min. The solvent was used at a flow rate of 200 ul/min, the columns temperature was kept constant at 25°C. The mass spectrometer operated in negative ion mode, settings of the HESI probe were as follows: sheath gas flow rate at 35, auxiliary gas flow rate at 14. Spray voltage was set at 2.9 kV, temperature of the capillary at 300°C and S-lens RF level at 50. A full scan (resolution of 240,000 and scan range of m/z 70-750) was applied. For the data analysis we used XCalibur version 4.2.28.14 (Thermo Scientific).

In vivo 13C metabolomics tracing

Mice were injected intra-peritoneally with 3 mL of Brewer thioglycollate medium (Sigma, B-2551) 4 days before sacrifice. The in vivo labeling strategy was based on Ogawa et al. (2018). The control solution was made by warming glycerol (Biosolve, 7122301) and adding of 10% glycerol and 4,8% lecithin. 13C labeled ethyl ester palmitic acid (Cambridge Isotope Laboratories, CLM-3957-0) was dissolved in lecithin (Wako chemicals, 120-00832) dropwise under heat, after which water was added dropwise under low heat to get a stock solution. Mice were injected intra-peritoneally with 3 mL of Brewer thioglycollate medium (Sigma, B-2551) 4 days before sacrifice. The intraperitoneal fluid was isolated. In short, 5 mL of PBS with 5 mM EDTA was injected intra-peritoneally with a small needle, the abdomen was gently massaged and most of the liquid was again retracted using a larger needle. The cells were spun down at 300 g for 3 min, the supernatants was removed and the pellet was dissolved in 250 ul of the aforementioned extraction buffer, spun down at 20000 g for 10 min at 4 degrees, after which the supernatants (5 ul) was analyzed on the LC-OrbiTRAP Lumos Fusion.

Analysis of mitochondrial function

Wild-type and A20 knockout HoxB8 cells or BMDMs were seeded in XFe96 cell culture plates (Agilent technologies) at a density of 500,000 cells/well in a XFe96 cell culture microplate a day before the experiment. OCR values were obtained from running mitochondrial stress tests according to the manufacturer’s instructions. During the assay, the sequential injections were done at the following concentrations: oligomycin – 1.5 μM, FCCP- 1.5 μM and rotenone/AntimycinA- 0.5 μM. In order to gauge the utilization of intrinsic fatty acid by wild-type and A20 knockout HoxB8 derived macrophages we performed the Seahorse XF Long Chain Fatty Acid Oxidation Stress Test Kit according to the manufacturer’s instructions. The drugs were used at the following concentrations for sequential injections- Etomoxir at 4 μM, oligomycin – 1.5 μM, FCCP- 1.5 μM and rotenone/AntimycinA- 0.5 μM.

Bone marrow transfer

Allogenic bone marrow transplants were performed 24 h after myeloablative total body irradiation (8 Gy) of recipient male mice (age ranging from 7-12 weeks). Donor bone marrow was isolated from the tibia and femur of female A20FL/FL LysM CreTG/+CCR2eGFPFL/+ and A20FL/FL LysM CreTG/+CCR2eGFPFL/+ mice. Bone marrow reconstitution was performed

Bone marrow transfer

Allogenic bone marrow transplants were performed 24 h after myeloablative total body irradiation (8 Gy) of recipient male mice (age ranging from 7-12 weeks). Donor bone marrow was isolated from the tibia and femur of female A20FL/FL LysM CreTG/+CCR2eGFPFL/+ and A20FL/FL LysM CreTG/+CCR2eGFPFL/+ mice. Bone marrow reconstitution was performed...
by intravenous injection of 5 × 10^6 bone marrow-derived cells in 200 mL of PBS 24 h after irradiation. After a recovery phase of 6 weeks, mice were fed with High Fat Diet as previously described.

qPCR

Tissues were harvested from mice and immediately frozen in liquid nitrogen. Tissues or cells were homogenized in TRIzol® (Thermo Fisher Scientific) using the TissueLyser II (QIAGEN). Chloroform was added (1:10) and after prolonged vortexing samples were centrifuged at 13,000 rpm. The upper phase was mixed with an equal volume of 70% ethanol, followed by RNA isolation according to manufacturer’s instructions using the Aurum total RNA mini kit (Bio-rad Laboratories). cDNA synthesis was performed using the iScript cDNA synthesis kit (Bio-Rad Laboratories) and 10 ng of cDNA was used for quantitative PCR in a total volume of 5 μl SensiFastSYBR No-ROX (Bioline) on the LightCycler 480 (Roche). Real-time PCR reactions were performed in triplicate using mouse-specific primers. Sequences of the mouse-specific primers are summarized in Table S1.

RNA-sequencing

Epididymal fat pads were digested in DMEM + 2% BSA supplemented with 0.28 U/ml Liberase TM (Roche) and 100 U/ml DNase I (Roche) at 37°C until single cell suspension. Cells were stained with the following antibodies: CD45-FITC (eBioscience, 11-0451), Siglec F-PE (BD, 552126), Ly6G-PE (BD, 551461), Ly6C-PE (BD, 560592), CD11c-PE-Cy7 (eBioscience, 250114), CD11b-BV421 (BD, 562605), CD64-BV711 (Biolegend, 139311), CD206-APC (Biolegend, 141707), F4/80-Biotin (eBioscience, 13-4801), Streptavidin-eFluor710 (BD, 563858), Fixable live dead stain eFluor780 (eBioscience, 65-0865). After filtration through a 30 μm filter the cells were sorted using the FACS ARIA III (BD) directly in RLT plus lysis buffer supplemented with β-mercaptoethanol and RNA was isolated using the RNasey Plus Micro Kit (QIAGEN) according to the manufacturer’s protocol. RNA quality was checked using the NanoDrop (Thermo Fisher Scientific) and the Agilent RNA 600 Nano kit (Agilent Technologies). Only samples with a RIN value above 8 were used. RNA samples were transcribed into cDNA and amplified using a SMART-Seq V4 Ultra Low Input kit (Takara) and a NEBNext Ultra DNA Library Prep kit (New England Biolabs), respectively, and sequenced on the Illumina NextSeq (Illumina) by the VIB Nucleomics Core Facility. The preprocessing of the RNA Seq samples was done by Trimomatic. The adapters were cut off and reads were trimmed when the quality dropped below 20. Reads with a length lower than 35 were discarded. All samples passed quality control based on the results of FastQC. Reads were mapped to the mouse reference genome (mm10) via Tophat2 and counted via HTSeqCount. Samples were subsequently analyzed using R/Bioconductor and the limma procedure was used to normalize and analyze the data. The PCA plot was created using the 15% of genes with the most variable expression. Heatmaps were normalized per mean expression of each gene in all samples. Regulatory networks were selected by Ingenuity Pathway Analysis (IPA) software. We used the online MSigDB webtool (https://www.gsea-msigdb.org/gsea/msigdb) to compute the overlap between our differentially expressed genes and the MSigDB Hallmark gene set. The Hallmark gene set was chosen as they are coherently expressed signatures derived by aggregating many MSigDB gene sets to represent well-defined biological states or processes.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data are represented as mean ± SEM. Statistical significance between experimental groups was assessed using 2-way ANOVA with a Sidak’s multiple comparison test. For the body weight, ipGTT and ITT analysis, the data were analyzed as longitudinal data (repeated-measurements over time) using the residual maximum likelihood (REML) as implemented in Genstat v19. Briefly, a linear mixed model (random terms underlined) of the form response = μ + treatment + time + treatment.time + subject.time was fitted to the longitudinal data. The term subject.time represents the residual error term with dependent errors because the repeated-measurements are taken repeatedly from the same subjects, causing correlations among observations. Times of measurement were set as equally spaced, and the best correlation model was selected based on the Aikake Information Coefficient (AIC). Significance of treatment effects over time (i.e., treatment.time) were assessed by an approximate F-test as implemented in Genstat v19. For the C16-Bodipy and 2-NBDG uptake studies: the experiments were laid out with 4 replicates having 1 to 4 observations per treatment, per cell type, per organ and per metabolite. The factor treatment has four levels referring to the 4 combinations of High Fat Diet (HFD) and Standard Diet (SD), with wild-type and knockout genotypes. Data were analyzed separately per organ and per metabolite. Because of the underlying Poisson distribution of cell count data, a log-linear regression model of the form g(u) = μ_0 + replicate, + celltype_j + treatment_k + celltype_j × treatment_k + ε_{ijkl}, with a log link function g(u) was fitted to the data. T statistics were used to assess the significance of treatment effects (on the log scale) by pairwise comparisons to the reference treatment. Estimated mean and standard error of the mean (sem) values were formed on the scale of the response variable.